

Information and Brokerage Event
Horizon Europe 2023 Call
Co-Funding opportunities by the Department of Biotechnology (DBT)
Gol.



Horizon Europe Brokerage Event

Friday, 13 October 2023

Virtual Event: Zoom ([Click here to register](#))

Topic:
Pandemic preparedness & Response: Host-pathogen interactions

Timing:
2:00 to 4:30pm Indian Time | 10:30 to 13:00pm Brussels Time

Agenda

2:00-2:10pm IST (10:30-10:40am CET)	Welcome Dr Samrat S. Kumar Country Coordinator, EURAXESS India Opening Remarks Mr. Pierrick Fillon-Ashida Counsellor, Head of Research & Innovation Section, EU Delegation to India Dr. Manish Rana Scientist 'F', International Cooperation Division, DBT
--	--



<p>2:10-2:30pm IST (10:30-11:00am CET)</p>	<p>Guidelines for Participation – Technical Aspect (EU DEL/ DBT)</p> <p>Dr. Vivek Dham Advisor Research & Innovation, EU Delegation to India</p>
<p>2:30-2:50pm IST (11:00-11:20am CET)</p>	<p>Presentation on the scope of call</p> <ul style="list-style-type: none"> • HORIZON-HLTH-2024-DISEASE-08-20: Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential (RIA) - Opening: 26 Oct 2023 Deadline(s): 11 Apr 2024 DBT <p>Speaker: Dr. Srin Kaveri Director, CNRS Bureau in India, French Embassy in India</p> <p>Questions and Answers</p>
<p>2:50-3:00pm IST (11.20-11.30am CET)</p>	<p>Questions & Answers</p> <p>Moderator: Dr. Samrat S. Kumar</p>
<p>3:00-4:20pm IST (11:30am-12:50pm CET)</p>	<p>Flash Presentation: Brokerage session European and Indian researchers, entrepreneurs and other stakeholders actively looking for project partners or wish to be part of consortium, can present their project idea or expertise during a flash presentation session.</p> <p>Maximum 7 min. per presentation</p> <p>Moderator: Dr. Samrat S. Kumar</p> <p>Cell-based live attenuated influenza vaccine (LAIV): Understanding immune repertoire and efficacy through human challenge studies Dr. Leena R Yeolekar & Dr.Parikshit Tyagi Serum Institute of India Pvt Ltd, Pune, India</p> <p>Resources for vaccine and antiviral research at the Viral BSI3, CIDR, IISc, India Prof. Shashank Tripathi Center for Infectious Disease Research, Indian Institute of Science, Bengaluru, India</p> <p>RespirAID R20 Mr. Gautham Pasupuleti CEO & Managing Director, Biodesign Innovation labs</p> <p>Development of COVID-19 prediction tool based on hematological parameters derived across the populations and integrated on machine learning platform Dr. Debashree Bandyopadhyay Birla Institute of Technology and Science, Pilani, Hyderabad Campus</p>

	<p>Pandemic preparedness: Novel mechanisms of bats in regulating pyroptosis, tissue damage and inflammation to tolerate pathogenic viruses Dr. Kesavardana Sannula Asst. Prof., Dept. of Biochemistry, Indian Institute of Science (IISc)</p> <p>Host-targeted therapeutics for infectious diseases with epidemic potential Prof. Amit Awashti Translational Health Science and Technology Institute</p> <p>High-throughput multiplexed antibody immuno-profiling technologies Dr. Rahul Roy Department of Chemical Engineering, Indian Institute of Science</p> <p>Novel treatment for drug resistant tuberculosis Prof. Gabriela Godaly Lund University, Sweden</p> <p>Questions & Answers</p>
<p>4:20-4:25pm IST (12:50am-12:55pm CET)</p>	<p>Challenges for matchmaking EU-India Dr. Michael Braun EU Expert</p>
<p>4:25-4:30pm IST (12:55am-13:00pm CET)</p>	<p>Closing Remarks Mr. Pierrick Fillon-Ashida Counsellor, Head of Research & Innovation Section, EU Delegation to India</p> <p>Dr. Abhishek Singh Scientist, International Cooperation Division, DBT</p>

